1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Feb 2024
Admin
News Article

Myriad Genetics Partners with NCCHE for Clinical Trials

Myriad Genetics and National Cancer Center Hospital East in Japan Partner on Pan-Cancer MRD Monitoring Clinical Trial: SCRUM-MONSTAR-SCREEN-3

Myriad Genetics, Inc. (NASDAQ: MYGN), a leading company in genetic testing and precision medicine, has announced a research collaboration with Japan's National Cancer Center Hospital East (NCCHE) to explore the prognostic and predictive potential of molecular residual disease (MRD) testing. This collaboration involves the SCRUM-MONSTAR-SCREEN-3 study, which will utilize Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) in patients diagnosed with various solid tumor and hematological cancers.

About SCRUM-MONSTAR-SCREEN-3 Study

Led by Dr. Takayuki Yoshino of NCCHE, the SCRUM-MONSTAR-SCREEN-3 study aims to leverage multi-omic profiling to devise more tailored treatment approaches across three study cohorts.
Approximately 1,200 patients spanning over 20 cancer types will participate in two of these cohorts, undergoing MRD monitoring via Precise MRD.
The study's objective is to generate robust prospective clinical evidence supporting the broad applicability of MRD testing across cancer types and different disease severities or stages.

Dr. Yoshino on the Potential of Study

Dr. Yoshino, Deputy Director of NCCHE and Head of the Division for the Promotion of Drug and Diagnostic Development, emphasized the need for an MRD test sensitive enough to detect ctDNA at low levels, particularly for cancers with minimal tumor shedding.
He underscored the uniqueness of Myriad's MRD assay in this aspect and highlighted the potential of the SCRUM-MONSTAR-SCREEN-3 study to redefine the landscape of whole-genome sequencing-based MRD projects, paving the way for MRD-guided therapeutic strategies across diverse cancer types.

Myriad Genetics’ Statement Over Partnership

Myriad Genetics, expressed excitement about collaborating with NCCHE on the SCRUM-MONSTAR-SCREEN-3 study, citing NCCHE's leadership in MRD research.
He noted NCCHE's involvement in groundbreaking trials like CIRCULATE-Japan, which includes GALAXY, VEGA, and ALTAIR trials in colorectal cancer patients.
Dr. Muzzey emphasized the design of Precise MRD to be highly sensitive across all cancer types and anticipated the study to showcase its efficacy in cancer management.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!